25.12

0.51% -0.13

After Hours: 25.12

Anaptysbio Inc (ANAB)

Overview News Price History Option Chain Financials Discussions Forecast

Anaptysbio Inc stock is traded at $25.12, with a volume of 410.32K. It is down -0.51% in the last 24 hours and down -21.57% over the past month. AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Previous Close:

$25.25

Open:

$25.61

24h Volume:

410.32K

Relative Volume:

1.03

Market Cap:

$763.76M

Revenue:

$17.16M

Net Income/Loss:

$-163.62M

P/E Ratio:

-4.8401

EPS:

-5.19

Net Cash Flow:

$-121.61M

1W Performance:

+23.68%

1M Performance:

-21.57%

6M Performance:

+5.06%

1Y Performance:

+80.72%

1-Day Range:

$24.73

$26.51

1-Week Range:

$20.23

$26.51

52-Week Range:

$13.36

$41.31

Anaptysbio Inc Stock (ANAB) Company Profile

Name

Anaptysbio Inc

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

858-362-6295

Address

10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA

Employee

117

Twitter

@anaptysbio

Next Earnings Date

2024-11-08

Latest SEC Filings

ANAB's Discussions on Twitter

Compare ANAB with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ANAB Anaptysbio Inc	25.12	763.76M	17.16M	-163.62M	-121.61M	-5.19
VRTX Vertex Pharmaceuticals Inc	464.56	119.70B	10.63B	-479.80M	-1.35B	13.33
REGN Regeneron Pharmaceuticals Inc	754.87	82.75B	13.85B	4.65B	3.32B	35.06
ARGX Argen X Se Adr	614.59	36.73B	1.86B	-40.29M	-1.28B	-4.16
ALNY Alnylam Pharmaceuticals Inc	253.74	32.53B	2.09B	-332.26M	16.06M	-4.14
BNTX Biontech Se Adr	120.72	28.50B	3.30B	-501.07M	1.03B	11.54

Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-22-24	Initiated	H.C. Wainwright	Buy
Jul-19-24	Upgrade	JP Morgan	Neutral → Overweight
Apr-16-24	Initiated	Leerink Partners	Outperform
Apr-11-24	Initiated	Wells Fargo	Overweight
Mar-12-24	Upgrade	Wedbush	Neutral → Outperform
Feb-26-24	Initiated	BTIG Research	Buy
Feb-21-24	Initiated	Stifel	Buy
Feb-16-24	Initiated	Piper Sandler	Overweight
May-22-23	Upgrade	JP Morgan	Underweight → Neutral
May-18-23	Initiated	TD Cowen	Outperform
Jan-06-23	Downgrade	Raymond James	Outperform → Mkt Perform
Nov-01-22	Upgrade	Guggenheim	Neutral → Buy
Sep-19-22	Resumed	H.C. Wainwright	Buy
Sep-13-22	Downgrade	Truist	Buy → Hold
Sep-01-22	Initiated	Raymond James	Outperform
Mar-22-22	Downgrade	Guggenheim	Buy → Neutral
Jun-22-21	Initiated	H.C. Wainwright	Buy
May-21-21	Initiated	UBS	Neutral
Mar-16-21	Upgrade	Truist	Hold → Buy
Mar-09-21	Downgrade	Wedbush	Outperform → Neutral
Mar-08-21	Downgrade	JP Morgan	Overweight → Underweight
Feb-11-21	Upgrade	JP Morgan	Underweight → Overweight
Oct-27-20	Upgrade	Wedbush	Neutral → Outperform
Oct-14-20	Upgrade	Guggenheim	Neutral → Buy
Nov-08-19	Downgrade	JP Morgan	Overweight → Underweight
Nov-08-19	Downgrade	Jefferies	Buy → Hold
Nov-08-19	Downgrade	SunTrust	Buy → Hold
Nov-08-19	Downgrade	Wedbush	Outperform → Neutral
Jun-21-19	Downgrade	Credit Suisse	Outperform → Neutral
Jun-21-19	Downgrade	Stifel	Buy → Hold
Dec-20-18	Initiated	H.C. Wainwright	Buy
Nov-21-18	Initiated	JP Morgan	Overweight
Jul-19-18	Initiated	Credit Suisse	Outperform
Apr-04-18	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Mar-27-18	Reiterated	Stifel	Buy
Mar-06-18	Reiterated	Stifel	Buy
Feb-15-18	Reiterated	SunTrust	Buy
Jan-23-18	Reiterated	Credit Suisse	Outperform
Nov-15-17	Initiated	SunTrust	Buy
Nov-09-17	Initiated	Jefferies	Buy
Oct-11-17	Reiterated	RBC Capital Mkts	Outperform
Sep-15-17	Initiated	RBC Capital Mkts	Outperform

View All

Anaptysbio Inc Stock (ANAB) Latest News

Nov 25, 2024

Are Medical Stocks Lagging AnaptysBio (ANAB) This Year? - Yahoo Finance

Nov 25, 2024

Nov 23, 2024

Jennison Associates LLC Makes New Investment in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat

Nov 23, 2024

Nov 22, 2024

Victory Capital Management Inc. Boosts Holdings in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat

Nov 22, 2024

Nov 21, 2024

AnaptysBio: An Immunology Pipeline-In-A-Pill Company Worth Watching - Seeking Alpha

Nov 21, 2024

Nov 20, 2024

Down -32.84% in 4 Weeks, Here's Why You Should You Buy the Dip in AnaptysBio (ANAB) - MSN

Nov 20, 2024

Nov 19, 2024

Truist maintains hold on AnaptysBio with $30 target By Investing.com - Investing.com UK

Nov 19, 2024

Nov 17, 2024

Analysts Set AnaptysBio, Inc. (NASDAQ:ANAB) Price Target at $54.64 - MarketBeat

Nov 17, 2024

AnaptysBio’s (ANAB) “Outperform” Rating Reiterated at Wedbush - Defense World

Nov 17, 2024

Nov 16, 2024

Broker Revenue Forecasts For AnaptysBio, Inc. (NASDAQ:ANAB) Are Surging Higher - Yahoo Finance

Nov 16, 2024

Nov 12, 2024

JPMorgan Chase & Co. Issues Pessimistic Forecast for AnaptysBio (NASDAQ:ANAB) Stock Price - MarketBeat

Nov 12, 2024

Nov 10, 2024

HC Wainwright Has Lowered Expectations for AnaptysBio (NASDAQ:ANAB) Stock Price - Defense World

Nov 08, 2024

AnaptysBio (NASDAQ:ANAB) Earns “Outperform” Rating from Wedbush - Defense World

Nov 08, 2024

What is Wedbush's Forecast for AnaptysBio FY2024 Earnings? - MarketBeat

Nov 08, 2024

Nov 07, 2024

Lilly bid wilts as others forge on with PD-1 in RA - BioWorld Online

Nov 07, 2024

AnaptysBio, Inc. (NASDAQ:ANAB) May Have Run Too Fast Too Soon With Recent 33% Price Plummet - Simply Wall St

Nov 07, 2024

AnaptysBio Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 07, 2024

AnaptysBio (NASDAQ:ANAB) Shares Gap Up Following Strong Earnings - Defense World

Nov 07, 2024

Nov 06, 2024